Business Context and Reporting Period
This Form 8-K, dated May 31, 2023, reports the completion of a merger transaction on June 1, 2023, between Angion Biomedica Corp. and Elicio Therapeutics, Inc. Following the merger, Angion changed its name to Elicio Therapeutics, Inc. (the "Company"). The transaction was structured as a reverse recapitalization, with Elicio treated as the accounting acquirer. The Company is now a clinical-stage biopharmaceutical firm focused on lymph node-targeting Amphiphile (AMP) technology, specifically developing ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors. The Company's headquarters are located in Boston, Massachusetts.
Key Financial Metrics and Capital Structure
This filing details the structural changes to the Company's capitalization rather than operational financial performance metrics such as revenue or profit, as the Company is a clinical-stage entity.
- Share Issuance: Angion issued an aggregate of 5,375,751 shares of common stock to Elicio stockholders (Exchange Shares).
- Exchange Ratio: Each outstanding share of Elicio capital stock was converted into the right to receive 0.0181 shares of Angion common stock.
- Post-Merger Ownership: Immediately following the merger, prior Elicio equityholders owned approximately 65.2% of the Company, and prior Angion equityholders owned approximately 34.8% on a fully diluted basis.
- Outstanding Shares: Approximately 9.7 million shares of common stock were outstanding on a fully diluted basis immediately after the merger.
- Reverse Stock Split: Angion common stock underwent a 10:1 reverse stock split effective June 1, 2023.
- Trading Symbol: The Company's common stock began trading on the Nasdaq Global Market under the ticker symbol "ELTX" on June 2, 2023.
The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels for the reporting period.
Material Changes Versus Prior Period
The primary material change is the completion of the Merger, resulting in a change of control and a shift in the Company's business focus from Angion's previous operations to Elicio's immunotherapy pipeline.
- Corporate Name: Changed from "Angion Biomedica Corp." to "Elicio Therapeutics, Inc."
- Board Composition: The board was reconstituted to include six designees of Elicio and three designees of Angion. Elicio designees hold a majority control of the board.
- Executive Leadership: Robert Connelly (former Elicio CEO) was appointed CEO and President. Brian Piekos was appointed CFO. Former Angion executives, including the former CFO and CEO, were terminated or resigned effective at the time of the merger.
- Accounting Firm: Moss Adams LLP was dismissed as the independent registered public accounting firm, and Baker Tilly US, LLP was engaged for the fiscal year ending December 31, 2023.
- Equity Plans: The Company assumed the Elicio 2012 and 2022 Equity Incentive Plans. Outstanding Elicio options and warrants were adjusted based on the 0.0181 exchange ratio.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Company's strategy, future operations, and the advancement of its product candidates, including ELI-002. Management anticipates realizing benefits from the merger, though actual results may differ materially.
Key Risks and Contingencies:
- Development Risks: Risks associated with the failure to realize anticipated benefits of the merger, the inability to advance product candidates under anticipated timelines, and the failure to replicate preclinical results in clinical trials.
- Regulatory Risks: Dependence on obtaining and maintaining approvals from the FDA and other regulatory authorities.
- Capital Requirements: Risks related to the inability to obtain sufficient additional capital to continue advancing product candidates and preclinical programs.
- Intellectual Property: Risks associated with obtaining, maintaining, and protecting IP rights related to product candidates.
Pro forma financial information and financial statements of the business acquired are to be filed by amendment within 71 calendar days of this report.
Important Facts for Investor Verification
- Verify the post-merger share count of approximately 9.7 million fully diluted shares and the ownership split (65.2% Elicio legacy, 34.8% Angion legacy).
- Confirm the new ticker symbol "ELTX" and the 10:1 reverse stock split adjustment for existing Angion shareholders.
- Review the employment agreements for new executive officers (CEO Robert Connelly, CFO Brian Piekos) regarding base salaries, bonus targets, and severance provisions.
- Monitor the upcoming filing of pro forma financial information and the financial statements of the acquired business (Elicio) within 71 days.
- Assess the status of the Company's primary asset, ELI-002, and the timeline for its clinical development as detailed in the referenced Risk Factors and MD&A exhibits.